SEEK is a leading privately-owned drug-discovery group whose technology and product pipeline is based upon a unique understanding of the human immune system. Headquartered in London, SEEK (formerly PepTcell) began life in 2004 with a pioneering scientific and commercially-driven approach to drug development.
SEEK is developing a broad pipeline of breakthrough medicines to address major disease areas. Its pipeline includes two novel vaccines against HIV and Flu which have successfully completed Phase II development. It is also developing differentiating low-cost small molecule drugs with short times-to-market in order to increase treatment availability for much larger patient populations.